查看購物車
  • English
  • Japanese
  • Korean
封面
市場調查報告書
商品編碼
2095323

呼吸道感染疾病診斷市場－全球市場預測（2026-2032年）

Respiratory Infection Diagnostics Market - Global Forecast 2026-2032
出版日期: | 出版商: 360iResearch | 英文 198 Pages | 商品交期: 最快1-2個工作天內

價格

※ 本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

預計到 2032 年，呼吸道感染疾病診斷市場將成長至 88.3 億美元，複合年成長率為 5.96%。

主要市場統計數據
基準年 2025 58.8億美元
預計年份：2026年 62.1億美元
預測年份 2032 88.3億美元
複合年成長率 (%) 5.96%

隨著季節性流感、呼吸道融合細胞病毒、SARS-CoV-2、細菌性肺炎、結核病以及新出現的呼吸道病原體持續給臨床工作流程、醫院容量和公共衛生監測帶來壓力，呼吸道感染疾病診斷已成為現代醫學的關鍵支柱。此領域涵蓋分子診斷、抗原檢測、血清學、培養方法、症候群特異性呼吸道病原體檢測、即時檢測以及用於識別病原體、制定治療策略、減少不合理使用抗生素和支持感染預防的數位化決策支援工具。對更快、更準確的呼吸道診斷檢測的需求源於以下三個方面：臨床上需要區分性行為感染和細菌性行為感染；運營上需要高效地對患者進行分診；以及公共衛生上需要及時、可比的數據來監測集體爆發。衛生組織持續優先考慮診斷品質、檢查室生物安全、合理使用抗生素和全面監測，從而加強了呼吸道傳染病檢查在醫院、中心檢查室、急診中心、藥房、社區診所和分散式醫療機構中的作用。隨著醫療保健系統從被動檢測轉向主動呼吸系統疾病管理，診斷策略越來越重視多病原體檢測、自動化樣本到結果的處理檢體、快速結果報告以及與電子健康記錄和公共衛生報告系統的整合。

呼吸系統診斷領域的變革性變化

呼吸道感染疾病診斷領域正經歷重大變革，其驅動力來自分子檢測、分散式醫療、症候群監測和緊急準備規劃的整合。核酸增幅檢查）以高分析靈敏度擴展了呼吸道病原體的檢測能力，而多重檢測組合則能夠從單一檢體同時鑑定流感病毒、SARS-CoV-2、呼吸道合胞病毒（RSV）、非典型細菌和其他臨床相關微生物。即時檢測（PoC）分子和抗原檢測正在改變檢測的可近性，支持急診、基層醫療機構、長期照護機構和社區醫療機構的快速決策。同時，檢查室正在採用自動化技術來減少人工操作時間、緩解人手不足並提高檢測結果的可重複性。公共衛生重點也在轉變；呼吸道診斷不再僅被視為個別患者照護的臨時工具，而是集體爆發檢測、合理使用抗菌藥物和應對疫情的基礎設施。監管機構的期望也在不斷變化，要求提供更強力的證據，以證明臨床性能、易用性、品管和上市後監測的有效性。醫療服務提供者越來越傾向於根據臨床效用、工作流程相容性、連接性、檢體類型柔軟性以及應對同期流行病原體季節性變化的能力來評估診斷平台。這些變化正在加速從單一病原體檢測模式轉變為根據臨床風險、當地流行病學背景和醫療資源活用狀況客製化的綜合呼吸道檢測流程的轉變。

人工智慧（AI）的累積影響

人工智慧 (AI) 透過增強檢測結果解讀、最佳化工作流程、利用影像進行分診、流行病學監測和決策支持，對呼吸道感染疾病的診斷產生了累積影響。在檢查室環境中，AI 驅動的分析可以幫助識別異常檢測模式、指出品管偏差、最佳化批量處理，並在呼吸道病毒爆發期間支援需求規劃。在臨床環境中，人們正在探索機器學習模型，以整合症狀、生命徵象、影像學觀察、實驗室結果、共病、疫苗接種史和當地病原體流行情況，從而支持風險分層和診斷路徑的選擇。 AI 在利用放射影像評估呼吸道感染疾病方面特別重要；演算法可用於幫助確定疑似肺炎或嚴重病毒性疾病病例的乳房攝影篩檢優先級，但檢查室確診對於病原體特異性診斷仍然至關重要。在公共衛生領域，基於 AI 的訊號檢測可以透過分析實驗室數據、污水指標、急診就診情況、藥房活動和流行病學趨勢來加強症候群監測。在呼吸道感染疾病診斷中負責任地使用人工智慧，需要檢驗的資料集、透明的效能指標、偏差評估、網路安全措施，以及遵守醫療設備和資料保護的法規。短期內，人工智慧最實際的益處預計體現在它能夠輔助而非取代臨床判斷的情況下。具體而言，這可能包括減少延誤、提高營運效率、支持合理使用抗生素以及實現呼吸道疾病叢集的早期發現。

各區域主要趨勢

在亞太地區，呼吸道感染疾病的診斷正透過對感染疾病監測的大規模投資、分子檢測網路的擴展以及在都市區醫療機構中提高即時檢測的可及性而不斷推進。在呼吸道疾病負擔沉重的人口稠密國家，快速識別流感、結核病、COVID-19、呼吸道合胞病毒（RSV）和細菌性肺炎的病原體是當務之急，同時區域性疫情防範計畫也在加強基因組監測和檢查室品管。在歐洲，健全的檢查室認證框架、跨境疾病監測、抗菌藥物抗藥性措施以及統一的臨床指南正在支持醫院和公共衛生網路中分子檢測和基於症候群的診斷方法的廣泛應用。北美地區仍然保持著較高的分子診斷普及率、成熟的法律規範體系、一體化的電子健康記錄記錄基礎設施以及完善的支付機制，這些都為醫院、參考檢查室、急診診所和藥房的檢測提供了支持。在該地區，診斷實踐越來越重視多參數呼吸道病原體檢測、合理使用抗生素以及在季節性感染高峰期進行監測報告。在拉丁美洲，透過公共衛生檢查室現代化、感染疾病監測和分散化舉措，診斷服務的可近性不斷擴大，但基礎設施不平衡、報銷限制和採購差異正在影響都市區和偏遠地區的部署模式。在非洲，各方致力於透過利用結核病檢測基礎設施、擴展分子檢測平台、加強檢體轉診網路以及將呼吸道監測與更廣泛的感染疾病項目相結合，來提高呼吸道診斷服務的公平可及性，但在供應連續性、人力資源開發和「最後一公里」服務方面仍然存在挑戰。在中東，透過醫院現代化、疫情防範以及對集中式和床邊檢測能力的投資，呼吸道診斷系統正在加強，尤其是在大規模集會和國家醫療衛生轉型計劃實施的國家。

關鍵小組洞察

儘管北約成員國並非醫療集團，但它們在生物安全、軍事戰備、疾病監測和具有韌性的醫療供應鏈方面共用通用的戰略利益，這凸顯了快速呼吸道疾病診斷在保護部隊健康、控制集體爆發和緊急應變計劃方面的重要性。七國集團（G7）國家普遍擁有強大的呼吸道疾病診斷能力、綜合監測系統、較高的分子檢測臨床普及率和先進的公共衛生報告基礎設施，使其在設定品質、臨床證據、合理使用抗菌藥物和戰備方面的預期方面具有影響力。金磚國家（BRICS）的診斷模式各不相同，它們擁有大規模的生產能力、龐大的患者群體、感染疾病負擔，並且對分子檢測設施的投資也在不斷增加，但獲取途徑、國內生產優先順序和採購模式方面的差異會影響其應用。歐盟透過協調的疾病監測、體外診斷醫療設備的監管要求、抗菌藥物抗藥性計畫和檢查室品質標準，為呼吸道疾病診斷提供了一個高度結構化的環境，從而促進了實證分子檢測和症候群檢測的實施。在東南亞國協，都市化、跨境流動、季節性流感爆發、結核病負擔以及應對疫情的準備工作是優先事項，這推動了對檢查室網路和分散式檢查的投資，並提高了對呼吸道感染疾病診斷的重視。儘管區域間合作正在協調監測工作，但發達的大都會圈醫療體系與資源匱乏地區在診斷服務取得方面仍有顯著差異。在海灣合作理事會（GCC）國家，在國家層面數位健康戰略、公共衛生準備工作以及應對與旅行、大型集會和日本僑民相關的呼吸道風險的需要的支持下，現代化醫院網路中先進呼吸道診斷平台的部署正在加速推進。

主要國家的概況

中國正大力推動呼吸道病原體監測、醫院檢查室自動化、國產診斷設備製造，並擴大多重檢測能力，以滿足大規模呼吸道疾病管理的需求。美國擁有高度發展的呼吸道感染診斷體系，這得益於分子檢測的廣泛應用、醫院和參考檢查室強大的檢測能力、急診科和藥房檢測管道的普及，以及對呼吸道病毒監測和合理抗菌藥物使用的重視。日本強調高品質的診斷、老化社會中的呼吸道感染疾病管理、醫院效率以及對流感、呼吸道合胞病毒（RSV）、SARS-CoV-2和肺炎相關病原體的快速檢測。印度正透過結核病分子診斷網路、公共衛生診斷項目、私人實驗室的擴建以及滿足不同醫療機構對價格合理的即時檢測工具的需求，來加強診斷服務的可及性。德國的優勢在於擁有完善的臨床實驗室基礎設施、高品質的標準以及廣泛的分子診斷臨床應用，同時也不斷完善高級檢測項目的保險報銷和證據要求。英國強調整合監測、基因組分析能力、臨床路徑最佳化，以及在醫院和社區醫療機構中推廣以管理為主導的呼吸道檢測。澳洲正在將呼吸道診斷與地理分散的醫療服務體系相結合，該體系兼顧全國範圍的監測、合理使用抗生素以及偏遠地區的醫療服務。法國將集中式公共衛生監管與醫院診斷能力結合，以支持流感、呼吸道合胞病毒（RSV）、新冠病毒（COVID-19）和抗生素抗藥性的監測。韓國憑藉其先進的分子檢測基礎設施、強大的數位健康合作以及以往的感染疾病應對經驗，展現出高度的準備水準。義大利和西班牙都將醫院呼吸道診斷、季節性病毒管理和疫情後應對準備放在首位，並在臨床需要時增加多重檢測和即時檢測方法的使用。加拿大則專注於公共衛生協調、省級檢查室網路和實證呼吸道檢測指南，並持續致力於確保偏遠地區和原住民社區的醫療服務可近性。俄羅斯擁有完善的感染疾病和結核病診斷體系，呼吸道檢測的部署受區域醫療基礎設施和國家診斷能力的影響。巴西在公共衛生檢測方面經驗豐富，感染疾病監測覆蓋範圍廣，但呼吸道診斷受到區域差異、公私合營服務體係以及對分子診斷平台持續投資的影響。墨西哥正在擴大其分子診斷和快速檢測能力，同時努力平衡公共部門採購、私人實驗室發展以及及時診斷流感、結核病、新冠肺炎和細菌性呼吸道感染疾病的需求。

為行業領導者提供的實用建議

行業領導者應優先考慮能夠提高臨床效用、速度、可及性和數據連接性的呼吸道感染疾病診斷策略，同時確保品質不受影響。開發人員和相關人員應根據當地流行病學背景、臨床指南和合理使用目標調整檢測項目，以確保在檢體結果可用於指導患者管理、隔離決策或調整抗生素處方時，使用多參數呼吸道檢測組合。投資於自動化樣本到結果流程、可擴展的生產系統、彈性供應鏈和方便用戶使用的即時檢測 (PoC) 工作流程，將有助於在季節性需求高峰和疫情爆發期間維持營運的連續性。診斷程序應與電子健康記錄、實驗室資訊系統和公共衛生報告平台實現互通性，將檢測結果轉化為可操作的監測資訊。領導者還應透過真實世界表現研究、健康經濟學評估、可用性測試和結果研究來加強證據生成，並專注於報告時間、住院決策、抗生素使用和感染控制的影響。在資源匱乏且地理分散的環境中，加強培訓、品質保證、檢體運輸和維護支援的夥伴關係對於永續部署至關重要。人工智慧工具應有選擇地實施，並納入檢驗、管治、隱私保護和偏差監測等措施。最重要的是，呼吸系統疾病的診斷策略應作為綜合診療路徑的一部分進行設計，將準確的檢測與及時的治療、隔離指南、疫苗宣傳活動和公共衛生應對措施聯繫起來。

調查方法

本執行摘要採用結構化的二手研究途徑編寫，重點檢驗的、有資料支持的資訊來源。這些資訊來源包括國際和國家公共衛生機構的指南和出版刊物、同行評審的臨床文獻、監管指令、臨床實驗室醫學標準、抗菌藥物管理材料、感染疾病監測報告以及經認可的衛生政策文件。分析優先考慮呼吸道病原體檢測方法、臨床效用、檢查室工作流程、公共衛生監測、監管要求、分散式診斷、人工智慧 (AI) 應用以及區域醫療保健基礎設施等方面的證據。資訊整合旨在識別不同地區、國家群體和主要國家市場的定性趨勢、應用促進因素、障礙和戰略意義。本調查方法不涉及市場規模估算、收入預測、市場佔有率計算和未來預測，而是專注於檢驗的流行病學相關性、技術應用模式、政策方向、診斷性能考慮以及醫療保健系統現狀。為提高可靠性，我們採用多資訊來源三角檢驗，強調公共衛生數據、臨床指引和科學證據之間的一致性。研究結果旨在幫助人們從策略角度了解當前呼吸道感染疾病診斷的現狀，同時保持中立性、實證嚴謹性和對決策者的實際意義。

結論

呼吸道感染疾病的診斷正從單一檢測轉向涵蓋臨床和公共衛生基礎設施的綜合模式。分子檢測、多重檢測、即時檢測、自動化、數位連接和人工智慧分析正在重塑這一領域，所有這些都有助於快速識別病原體並做出更明智的臨床決策。區域和國家的發展趨勢差異顯著；先進的醫療保健系統優先考慮綜合監測和複雜的分子檢測流程，而新興經濟體和資源匱乏地區則強調公平獲取醫療服務、增強檢查室能力和可擴展的快速檢測。最有效的診斷策略是將準確的檢測結果與可衡量的臨床措施聯繫起來，例如合理使用抗病毒藥物和抗生素、患者分診、感染預防和集體爆發應對。隨著呼吸道病原體的持續共存和演變，醫療保健系統需要準確、適應性強、可互通且具韌性的診斷方法。那些投資於實證部署、品質保證、數據整合和永續取得的領導者，將更有能力改善呼吸道疾病管理，並加強應對未來感染疾病威脅的準備工作。

目錄

第1章：序言

第2章：調查方法

  • 調查設計
  • 研究框架
  • 市場規模預測
  • 數據三角測量
  • 調查結果
  • 調查的前提
  • 研究限制

第3章執行摘要

  • 首席主管觀點
  • 市場規模和成長趨勢
  • 新的商機
  • 下一代經營模式
  • 產業藍圖

第4章 市場概覽

  • 產業生態系與價值鏈分析
  • 市場動態
  • 波特五力分析
  • PESTLE分析
  • 市場展望
  • 市場進入策略

第5章 市場洞察

  • 消費者洞察與終端用戶觀點
  • 消費者體驗基準
  • 機會映射
  • 分銷通路分析
  • 價格趨勢分析
  • 監理合規和標準框架
  • ESG與永續性分析
  • 中斷和風險情景
  • 投資報酬率和成本效益分析

第6章：人工智慧的累積影響，2026年

第7章 呼吸道感染疾病診斷市場：依技術分類

  • 免疫檢測
    • 酵素免疫分析法（ELISA）
    • 側向流動免疫檢測
  • 微生物培養
    • 自動化培養系統
    • 傳統培養方法
  • 分子診斷
    • 恒溫環型核酸擴增
    • 聚合酵素鏈鎖反應
  • 定序
    • 次世代定序
    • 桑格定序

第8章 呼吸道感染疾病診斷市場：依樣本類型分類

  • 血
  • 鼻拭子
  • 唾液
  • 痰
  • 咽拭子

第9章 呼吸道感染疾病診斷市場：依檢測方法分類

  • 檢查室基地
  • 照護現場

第10章 呼吸道感染疾病診斷市場：依最終使用者分類

  • 診所
  • 居家醫療
  • 醫院
  • 研究所

第11章 呼吸道感染疾病診斷市場：依感染類型分類

  • 流感
  • 呼吸道融合細胞病毒

第12章 呼吸道感染疾病診斷市場：按地區分類

  • 亞太地區
  • 歐洲
  • 北美洲
  • 拉丁美洲
  • 非洲
  • 中東

第13章 呼吸道感染疾病診斷市場：依組別分類

  • NATO
  • G7
  • BRICS
  • EU
  • ASEAN
  • GCC

第14章 呼吸道感染疾病診斷市場：依國家分類

  • 中國
  • 美國
  • 日本
  • 印度
  • 德國
  • 英國
  • 澳洲
  • 法國
  • 韓國
  • 義大利
  • 加拿大
  • 俄羅斯
  • 巴西
  • 墨西哥
  • 西班牙

第15章 競爭格局

  • 2025年市佔率分析
  • FPNV定位矩陣，2025
  • 市場集中度分析，2025年
    • 濃度比（CR）
    • 赫芬達爾-赫希曼指數 (HHI)
  • 近期趨勢及影響分析，2025 年
  • 2025年產品系列分析
  • 基準分析，2025 年

第16章：公司簡介

  • Abbott Laboratories
  • Becton Dickinson and Company
  • Bio-Rad Laboratories Inc
  • bioMerieux SA
  • Danaher Corporation
  • DiaSorin SpA
  • Dragerwerk AG & Co. KGaA
  • Eurofins Scientific SE
  • F. Hoffmann-La Roche Ltd
  • GE HealthCare Technologies Inc
  • Grifols SA
  • Hologic Inc
  • Illumina Inc
  • Masimo Corporation
  • Medtronic plc
  • Nihon Kohden Corporation
  • Oxford Nanopore Technologies plc
  • PerkinElmer Inc
  • Qiagen NV
  • QuidelOrtho Corporation
  • ResMed Inc
  • Revvity Inc
  • SD Biosensor Inc
  • Seegene Inc
  • Siemens Healthineers AG
  • Sysmex Corporation
  • Tecan Group Ltd
  • Thermo Fisher Scientific Inc
Product Code: MRR-02026C4C8612

The Respiratory Infection Diagnostics Market is projected to grow by USD 8.83 billion at a CAGR of 5.96% by 2032.

KEY MARKET STATISTICS
Base Year [2025] USD 5.88 billion
Estimated Year [2026] USD 6.21 billion
Forecast Year [2032] USD 8.83 billion
CAGR (%) 5.96%

Respiratory infection diagnostics have become a critical pillar of modern healthcare as seasonal influenza, respiratory syncytial virus, SARS-CoV-2, bacterial pneumonia, tuberculosis, and emerging respiratory pathogens continue to pressure clinical workflows, hospital capacity, and public health surveillance. The field spans molecular diagnostics, antigen detection, serology, culture-based methods, syndromic respiratory panels, point-of-care testing, and digital decision-support tools used to identify pathogens, guide treatment, reduce inappropriate antimicrobial use, and support infection prevention. Demand for faster and more accurate respiratory diagnostic testing is being shaped by the clinical need to distinguish viral from bacterial infections, the operational need to triage patients efficiently, and the public health need to monitor outbreaks with timely, comparable data. Health agencies continue to emphasize diagnostic quality, laboratory biosafety, antimicrobial stewardship, and surveillance integration, reinforcing the role of respiratory infection testing across hospitals, reference laboratories, urgent care centers, pharmacies, community clinics, and decentralized care settings. As healthcare systems shift from reactive testing to preparedness-oriented respiratory disease management, diagnostic strategies increasingly prioritize multiplex pathogen detection, sample-to-answer automation, rapid turnaround time, and connectivity with electronic health records and public health reporting systems.

Transformative Shifts in the Respiratory Diagnostics Landscape

The respiratory infection diagnostics landscape is undergoing significant transformation driven by the convergence of molecular testing, decentralized care, syndromic surveillance, and preparedness planning. Nucleic acid amplification tests have expanded the ability to detect respiratory pathogens with high analytical sensitivity, while multiplex panels enable simultaneous identification of influenza viruses, SARS-CoV-2, RSV, atypical bacteria, and other clinically relevant organisms from a single specimen. Point-of-care molecular and antigen tests are reshaping access by supporting rapid decisions in emergency departments, primary care offices, long-term care facilities, and community-based settings. At the same time, laboratories are adopting automation to reduce hands-on time, mitigate workforce constraints, and improve reproducibility. Public health priorities have also shifted: respiratory diagnostics are no longer viewed only as episodic tools for individual patient care but as infrastructure for outbreak detection, antimicrobial stewardship, and pandemic readiness. Regulatory expectations are evolving toward stronger evidence of clinical performance, usability, quality management, and post-market monitoring. Healthcare providers are increasingly evaluating diagnostic platforms based on clinical utility, workflow fit, connectivity, sample type flexibility, and capacity to support co-circulating pathogen seasons. These shifts are accelerating a move from single-pathogen testing models toward integrated respiratory testing pathways aligned with clinical risk, local epidemiology, and healthcare resource utilization.

Cumulative Impact of Artificial Intelligence

Artificial intelligence is having a cumulative impact on respiratory infection diagnostics by strengthening test interpretation, workflow prioritization, imaging triage, epidemiological surveillance, and decision support. In laboratory environments, AI-enabled analytics can help identify unusual testing patterns, flag quality-control deviations, optimize batching, and support demand planning during respiratory virus surges. In clinical settings, machine learning models are being explored to combine symptoms, vital signs, imaging findings, laboratory results, comorbidities, vaccination history, and local pathogen prevalence to support risk stratification and diagnostic pathway selection. AI has particular relevance in radiology-assisted respiratory infection assessment, where algorithms can help prioritize chest imaging studies for suspected pneumonia or severe viral disease, although laboratory confirmation remains essential for pathogen-specific diagnosis. For public health, AI-based signal detection can enhance syndromic surveillance by analyzing laboratory data, wastewater indicators, emergency visits, pharmacy activity, and epidemiological trends. The responsible use of AI in respiratory infection diagnostics requires validated datasets, transparent performance metrics, bias assessment, cybersecurity safeguards, and compliance with medical device and data protection regulations. The most practical near-term impact is expected where AI augments rather than replaces clinical judgment: reducing delays, improving operational efficiency, supporting antimicrobial stewardship, and enabling earlier recognition of respiratory disease clusters.

Key Regional Insights

Asia-Pacific is advancing respiratory infection diagnostics through large-scale infectious disease surveillance investments, expanding molecular laboratory networks, and rising adoption of point-of-care testing across urban and rural healthcare settings. Countries with dense populations and high respiratory disease burdens are prioritizing faster pathogen identification for influenza, tuberculosis, COVID-19, RSV, and bacterial pneumonia, while regional preparedness programs are strengthening genomic surveillance and laboratory quality systems. Europe benefits from strong laboratory accreditation frameworks, cross-border disease monitoring, antimicrobial resistance strategies, and clinical guideline alignment, supporting broad use of molecular testing and syndromic approaches across hospital and public health networks. North America remains characterized by high adoption of molecular diagnostics, mature regulatory oversight, integrated electronic health record infrastructure, and established payment pathways that support hospital, reference laboratory, urgent care, and pharmacy-based testing. The region's diagnostic practices increasingly emphasize multiplex respiratory panels, antimicrobial stewardship, and surveillance reporting during seasonal surges. Latin America continues to expand diagnostic access through public health laboratory modernization, infectious disease surveillance, and decentralization initiatives, although uneven infrastructure, reimbursement limitations, and procurement variability influence adoption patterns across urban and remote areas. Africa is focused on improving equitable access to respiratory diagnostics by leveraging tuberculosis laboratory infrastructure, expanding molecular testing platforms, strengthening specimen referral networks, and integrating respiratory surveillance with broader infectious disease programs, while challenges persist around supply continuity, workforce training, and last-mile access. The Middle East is strengthening respiratory diagnostics through hospital modernization, outbreak preparedness, and investment in centralized and near-patient testing capabilities, particularly in countries with high international travel flows, large gatherings, and national health transformation programs.

Key Group Insights

NATO member countries, while not a healthcare bloc, share strategic interest in biosecurity, military readiness, disease surveillance, and resilient medical supply chains, reinforcing the relevance of rapid respiratory diagnostics for force health protection, outbreak containment, and emergency response planning. G7 countries generally demonstrate strong respiratory diagnostic capacity, integrated surveillance systems, high clinical adoption of molecular testing, and advanced public health reporting infrastructure, making them influential in setting expectations for quality, clinical evidence, antimicrobial stewardship, and preparedness. BRICS nations represent diverse diagnostic conditions, combining major manufacturing capacity, large patient populations, infectious disease burden, and growing investment in molecular laboratories, while access disparities, domestic production priorities, and procurement models shape implementation. The European Union provides a highly structured environment for respiratory diagnostics through coordinated disease surveillance, in vitro diagnostic regulatory requirements, antimicrobial resistance action plans, and laboratory quality standards, encouraging evidence-based implementation of molecular and syndromic testing. ASEAN countries are increasing attention on respiratory infection diagnostics as urbanization, cross-border mobility, seasonal influenza activity, tuberculosis burden, and pandemic preparedness priorities drive investment in laboratory networks and decentralized testing. Regional collaboration supports surveillance harmonization, although diagnostic access varies widely between advanced metropolitan health systems and lower-resource settings. GCC countries are accelerating adoption of advanced respiratory diagnostic platforms within modern hospital networks, supported by national digital health strategies, public health preparedness, and the need to manage respiratory risks associated with travel, mass gatherings, and expatriate populations.

Key Country Insights

China is expanding respiratory pathogen surveillance, hospital laboratory automation, domestic diagnostic manufacturing, and multiplex testing capability in response to large-scale respiratory disease management needs. The United States has a highly developed respiratory infection diagnostics environment supported by broad use of molecular testing, extensive hospital and reference laboratory capacity, urgent care adoption, pharmacy testing channels, and strong emphasis on respiratory virus surveillance and antimicrobial stewardship. Japan emphasizes high-quality diagnostics, aging-population respiratory risk management, hospital efficiency, and rapid testing for influenza, RSV, SARS-CoV-2, and pneumonia-related pathogens. India is strengthening access through tuberculosis molecular networks, public health diagnostics programs, private laboratory expansion, and demand for affordable point-of-care tools across diverse healthcare settings. Germany benefits from strong laboratory medicine infrastructure, high-quality standards, and broad clinical access to molecular diagnostics, while continuing to refine reimbursement and evidence requirements for advanced panels. The United Kingdom emphasizes integrated surveillance, genomic capability, clinical pathway optimization, and stewardship-driven use of respiratory testing across hospitals and community care. Australia integrates respiratory diagnostics with national surveillance, antimicrobial stewardship, and geographically distributed healthcare delivery, including remote access considerations. France combines centralized public health oversight with hospital-based diagnostic strength, supporting influenza, RSV, COVID-19, and antimicrobial resistance monitoring. South Korea demonstrates advanced molecular testing infrastructure, strong digital health connectivity, and high preparedness orientation informed by prior infectious disease response experience. Italy and Spain both prioritize hospital-based respiratory diagnostics, seasonal virus management, and post-pandemic preparedness, with increasing use of multiplex and point-of-care approaches where clinically justified. Canada focuses on public health coordination, provincial laboratory networks, and evidence-based respiratory testing guidance, with ongoing attention to access across remote and Indigenous communities. Russia maintains extensive infectious disease and tuberculosis diagnostic programs, with respiratory testing adoption influenced by regional healthcare infrastructure and domestic diagnostic capability. Brazil has significant public health laboratory experience and a large infectious disease surveillance footprint, with respiratory diagnostics shaped by regional disparities, public-private service delivery, and ongoing investments in molecular platforms. Mexico is expanding molecular and rapid testing capacity while balancing public sector procurement, private laboratory growth, and the need for timely diagnosis of influenza, tuberculosis, COVID-19, and bacterial respiratory infections.

Actionable Recommendations for Industry Leaders

Industry leaders should prioritize respiratory infection diagnostic strategies that improve clinical utility, speed, access, and data connectivity without compromising quality. Developers and healthcare stakeholders should align test menus with local epidemiology, clinical guidelines, and stewardship objectives, ensuring that multiplex respiratory panels are used where results can change patient management, isolation decisions, or antimicrobial prescribing. Investment in sample-to-answer automation, scalable manufacturing, resilient supply chains, and user-friendly point-of-care workflows can help maintain continuity during seasonal surges and outbreaks. Diagnostic programs should incorporate interoperability with electronic health records, laboratory information systems, and public health reporting platforms to convert test results into actionable surveillance intelligence. Leaders should also strengthen evidence generation through real-world performance studies, health economic evaluation, usability testing, and outcomes research focused on turnaround time, hospitalization decisions, antibiotic use, and infection control impact. In lower-resource or geographically dispersed settings, partnerships that improve training, quality assurance, specimen transport, and maintenance support are essential for sustainable implementation. AI-enabled tools should be adopted selectively, with validation, governance, privacy protection, and bias monitoring built into deployment. Above all, respiratory diagnostics strategies should be designed as part of integrated care pathways that connect accurate testing with timely treatment, isolation guidance, vaccination campaigns, and public health response.

Research Methodology

This executive summary is developed using a structured secondary research approach focused on verified, data-backed sources, including guidance and publications from global and national public health agencies, peer-reviewed clinical literature, regulatory communications, laboratory medicine standards, antimicrobial stewardship resources, infectious disease surveillance reports, and recognized healthcare policy documentation. The analysis prioritizes evidence related to respiratory pathogen testing methods, clinical utility, laboratory workflows, public health surveillance, regulatory expectations, decentralized diagnostics, artificial intelligence applications, and regional healthcare infrastructure. Information is synthesized to identify qualitative trends, adoption drivers, barriers, and strategic implications across regions, country groups, and key national markets. The methodology excludes market sizing, revenue estimation, market share calculation, and forecasting, and instead focuses on validated epidemiological relevance, technology adoption patterns, policy direction, diagnostic performance considerations, and healthcare system readiness. Cross-source triangulation is used to improve reliability, with emphasis on consistency across public health data, clinical guidelines, and scientific evidence. The resulting insights are intended to support strategic understanding of the respiratory infection diagnostics landscape while maintaining neutrality, evidence discipline, and practical relevance for decision-makers.

Conclusion

Respiratory infection diagnostics are moving from isolated test events toward integrated clinical and public health infrastructure. The sector is being reshaped by molecular testing, multiplex panels, point-of-care access, automation, digital connectivity, and AI-assisted analytics, all of which support faster pathogen identification and more informed care decisions. Regional and country-level dynamics differ substantially, with advanced health systems emphasizing integrated surveillance and sophisticated molecular workflows, while emerging and resource-constrained settings focus on equitable access, laboratory strengthening, and scalable rapid testing. The most effective diagnostic strategies will be those that connect accurate results to measurable clinical action, including appropriate antiviral or antibiotic use, patient triage, infection prevention, and outbreak response. As respiratory pathogens continue to co-circulate and evolve, healthcare systems will require diagnostics that are accurate, adaptable, interoperable, and resilient. Leaders that invest in evidence-based implementation, quality assurance, data integration, and sustainable access will be best positioned to improve respiratory disease management and strengthen preparedness for future infectious threats.

Table of Contents

1. Preface

  • 1.1. Objectives of the Study
  • 1.2. Market Definition
  • 1.3. Market Segmentation & Coverage
  • 1.4. Years Considered for the Study
  • 1.5. Currency Considered for the Study
  • 1.6. Language Considered for the Study
  • 1.7. Key Stakeholders

2. Research Methodology

  • 2.1. Introduction
  • 2.2. Research Design
    • 2.2.1. Primary Research
    • 2.2.2. Secondary Research
  • 2.3. Research Framework
    • 2.3.1. Qualitative Analysis
    • 2.3.2. Quantitative Analysis
  • 2.4. Market Size Estimation
    • 2.4.1. Top-Down Approach
    • 2.4.2. Bottom-Up Approach
  • 2.5. Data Triangulation
  • 2.6. Research Outcomes
  • 2.7. Research Assumptions
  • 2.8. Research Limitations

3. Executive Summary

  • 3.1. Introduction
  • 3.2. CXO Perspective
  • 3.3. Market Size & Growth Trends
  • 3.4. New Revenue Opportunities
  • 3.5. Next-Generation Business Models
  • 3.6. Industry Roadmap

4. Market Overview

  • 4.1. Introduction
  • 4.2. Industry Ecosystem & Value Chain Analysis
    • 4.2.1. Supply-Side Analysis
    • 4.2.2. Demand-Side Analysis
    • 4.2.3. Stakeholder Analysis
  • 4.3. Market Dynamics
    • 4.3.1. Key Drivers
    • 4.3.2. Key Restraints
    • 4.3.3. Key Opportunities
    • 4.3.4. Key Challenges
  • 4.4. Porter's Five Forces Analysis
  • 4.5. PESTLE Analysis
  • 4.6. Market Outlook
    • 4.6.1. Near-Term Market Outlook (0-2 Years)
    • 4.6.2. Medium-Term Market Outlook (3-5 Years)
    • 4.6.3. Long-Term Market Outlook (5-10 Years)
  • 4.7. Go-to-Market Strategy

5. Market Insights

  • 5.1. Consumer Insights & End-User Perspective
  • 5.2. Consumer Experience Benchmarking
  • 5.3. Opportunity Mapping
  • 5.4. Distribution Channel Analysis
  • 5.5. Pricing Trend Analysis
  • 5.6. Regulatory Compliance & Standards Framework
  • 5.7. ESG & Sustainability Analysis
  • 5.8. Disruption & Risk Scenarios
  • 5.9. Return on Investment & Cost-Benefit Analysis

6. Cumulative Impact of Artificial Intelligence 2026

7. Respiratory Infection Diagnostics Market, by Technology

  • 7.1. Introduction
  • 7.2. Immunoassay
    • 7.2.1. Enzyme Linked Immunosorbent Assay
    • 7.2.2. Lateral Flow Immunoassay
  • 7.3. Microbiological Culture
    • 7.3.1. Automated Culture Systems
    • 7.3.2. Conventional Culture
  • 7.4. Molecular Diagnostics
    • 7.4.1. Loop Mediated Isothermal Amplification
    • 7.4.2. Polymerase Chain Reaction
  • 7.5. Sequencing
    • 7.5.1. Next Generation Sequencing
    • 7.5.2. Sanger Sequencing

8. Respiratory Infection Diagnostics Market, by Sample Type

  • 8.1. Introduction
  • 8.2. Blood
  • 8.3. Nasal Swab
  • 8.4. Saliva
  • 8.5. Sputum
  • 8.6. Throat Swab

9. Respiratory Infection Diagnostics Market, by Test Mode

  • 9.1. Introduction
  • 9.2. Laboratory Based
  • 9.3. Point Of Care

10. Respiratory Infection Diagnostics Market, by End User

  • 10.1. Introduction
  • 10.2. Clinics
  • 10.3. Home Care Settings
  • 10.4. Hospitals
  • 10.5. Research Laboratories

11. Respiratory Infection Diagnostics Market, by Infection Type

  • 11.1. Introduction
  • 11.2. Influenza
  • 11.3. Respiratory Syncytial Virus

12. Respiratory Infection Diagnostics Market, by Region

  • 12.1. Asia-Pacific
  • 12.2. Europe
  • 12.3. North America
  • 12.4. Latin America
  • 12.5. Africa
  • 12.6. Middle East

13. Respiratory Infection Diagnostics Market, by Group

  • 13.1. NATO
  • 13.2. G7
  • 13.3. BRICS
  • 13.4. European Union
  • 13.5. ASEAN
  • 13.6. GCC

14. Respiratory Infection Diagnostics Market, by Country

  • 14.1. China
  • 14.2. United States
  • 14.3. Japan
  • 14.4. India
  • 14.5. Germany
  • 14.6. United Kingdom
  • 14.7. Australia
  • 14.8. France
  • 14.9. South Korea
  • 14.10. Italy
  • 14.11. Canada
  • 14.12. Russia
  • 14.13. Brazil
  • 14.14. Mexico
  • 14.15. Spain

15. Competitive Landscape

  • 15.1. Market Share Analysis, 2025
  • 15.2. FPNV Positioning Matrix, 2025
  • 15.3. Market Concentration Analysis, 2025
    • 15.3.1. Concentration Ratio (CR)
    • 15.3.2. Herfindahl Hirschman Index (HHI)
  • 15.4. Recent Developments & Impact Analysis, 2025
  • 15.5. Product Portfolio Analysis, 2025
  • 15.6. Benchmarking Analysis, 2025

16. Company Profiles

  • 16.1. Abbott Laboratories
  • 16.2. Becton Dickinson and Company
  • 16.3. Bio-Rad Laboratories Inc
  • 16.4. bioMerieux S.A.
  • 16.5. Danaher Corporation
  • 16.6. DiaSorin S.p.A.
  • 16.7. Dragerwerk AG & Co. KGaA
  • 16.8. Eurofins Scientific SE
  • 16.9. F. Hoffmann-La Roche Ltd
  • 16.10. GE HealthCare Technologies Inc
  • 16.11. Grifols S.A.
  • 16.12. Hologic Inc
  • 16.13. Illumina Inc
  • 16.14. Masimo Corporation
  • 16.15. Medtronic plc
  • 16.16. Nihon Kohden Corporation
  • 16.17. Oxford Nanopore Technologies plc
  • 16.18. PerkinElmer Inc
  • 16.19. Qiagen N.V.
  • 16.20. QuidelOrtho Corporation
  • 16.21. ResMed Inc
  • 16.22. Revvity Inc
  • 16.23. SD Biosensor Inc
  • 16.24. Seegene Inc
  • 16.25. Siemens Healthineers AG
  • 16.26. Sysmex Corporation
  • 16.27. Tecan Group Ltd
  • 16.28. Thermo Fisher Scientific Inc

LIST OF FIGURES

  • FIGURE 1. GLOBAL RESPIRATORY INFECTION DIAGNOSTICS MARKET, YEARS CONSIDERED FOR THE STUDY
  • FIGURE 2. GLOBAL RESPIRATORY INFECTION DIAGNOSTICS MARKET, RESEARCH DESIGN
  • FIGURE 3. GLOBAL RESPIRATORY INFECTION DIAGNOSTICS MARKET, RESEARCH FRAMEWORK
  • FIGURE 4. GLOBAL RESPIRATORY INFECTION DIAGNOSTICS MARKET, DATA TRIANGULATION
  • FIGURE 5. GLOBAL RESPIRATORY INFECTION DIAGNOSTICS MARKET SIZE, 2018-2032 (USD MILLION)
  • FIGURE 6. GLOBAL RESPIRATORY INFECTION DIAGNOSTICS MARKET SIZE, BY TECHNOLOGY, 2025 VS 2032 (%)
  • FIGURE 7. GLOBAL RESPIRATORY INFECTION DIAGNOSTICS MARKET SIZE, BY TECHNOLOGY, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 8. GLOBAL RESPIRATORY INFECTION DIAGNOSTICS MARKET SIZE, BY SAMPLE TYPE, 2025 VS 2032 (%)
  • FIGURE 9. GLOBAL RESPIRATORY INFECTION DIAGNOSTICS MARKET SIZE, BY SAMPLE TYPE, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 10. GLOBAL RESPIRATORY INFECTION DIAGNOSTICS MARKET SIZE, BY TEST MODE, 2025 VS 2032 (%)
  • FIGURE 11. GLOBAL RESPIRATORY INFECTION DIAGNOSTICS MARKET SIZE, BY TEST MODE, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 12. GLOBAL RESPIRATORY INFECTION DIAGNOSTICS MARKET SIZE, BY END USER, 2025 VS 2032 (%)
  • FIGURE 13. GLOBAL RESPIRATORY INFECTION DIAGNOSTICS MARKET SIZE, BY END USER, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 14. GLOBAL RESPIRATORY INFECTION DIAGNOSTICS MARKET SIZE, BY INFECTION TYPE, 2025 VS 2032 (%)
  • FIGURE 15. GLOBAL RESPIRATORY INFECTION DIAGNOSTICS MARKET SIZE, BY INFECTION TYPE, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 16. GLOBAL RESPIRATORY INFECTION DIAGNOSTICS MARKET SIZE, BY REGION, 2025 VS 2032 (%)
  • FIGURE 17. GLOBAL RESPIRATORY INFECTION DIAGNOSTICS MARKET SIZE, BY REGION, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 18. GLOBAL RESPIRATORY INFECTION DIAGNOSTICS MARKET SIZE, BY GROUP, 2025 VS 2032 (%)
  • FIGURE 19. GLOBAL RESPIRATORY INFECTION DIAGNOSTICS MARKET SIZE, BY GROUP, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 20. GLOBAL RESPIRATORY INFECTION DIAGNOSTICS MARKET SIZE, BY COUNTRY, 2025 VS 2032 (%)
  • FIGURE 21. GLOBAL RESPIRATORY INFECTION DIAGNOSTICS MARKET SIZE, BY COUNTRY, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 22. GLOBAL RESPIRATORY INFECTION DIAGNOSTICS MARKET SHARE, BY KEY PLAYER, 2025
  • FIGURE 23. GLOBAL RESPIRATORY INFECTION DIAGNOSTICS MARKET, FPNV POSITIONING MATRIX, BY KEY PLAYER, 2025

LIST OF TABLES

  • TABLE 1. GLOBAL RESPIRATORY INFECTION DIAGNOSTICS MARKET SEGMENTATION & COVERAGE
  • TABLE 2. GLOBAL RESPIRATORY INFECTION DIAGNOSTICS MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 3. GLOBAL RESPIRATORY INFECTION DIAGNOSTICS MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 4. GLOBAL IMMUNOASSAY MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 5. GLOBAL IMMUNOASSAY MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 6. GLOBAL IMMUNOASSAY MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 7. GLOBAL ENZYME LINKED IMMUNOSORBENT ASSAY MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 8. GLOBAL ENZYME LINKED IMMUNOSORBENT ASSAY MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 9. GLOBAL ENZYME LINKED IMMUNOSORBENT ASSAY MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 10. GLOBAL LATERAL FLOW IMMUNOASSAY MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 11. GLOBAL LATERAL FLOW IMMUNOASSAY MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 12. GLOBAL LATERAL FLOW IMMUNOASSAY MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 13. GLOBAL MICROBIOLOGICAL CULTURE MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 14. GLOBAL MICROBIOLOGICAL CULTURE MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 15. GLOBAL MICROBIOLOGICAL CULTURE MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 16. GLOBAL AUTOMATED CULTURE SYSTEMS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 17. GLOBAL AUTOMATED CULTURE SYSTEMS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 18. GLOBAL AUTOMATED CULTURE SYSTEMS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 19. GLOBAL CONVENTIONAL CULTURE MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 20. GLOBAL CONVENTIONAL CULTURE MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 21. GLOBAL CONVENTIONAL CULTURE MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 22. GLOBAL MOLECULAR DIAGNOSTICS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 23. GLOBAL MOLECULAR DIAGNOSTICS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 24. GLOBAL MOLECULAR DIAGNOSTICS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 25. GLOBAL LOOP MEDIATED ISOTHERMAL AMPLIFICATION MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 26. GLOBAL LOOP MEDIATED ISOTHERMAL AMPLIFICATION MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 27. GLOBAL LOOP MEDIATED ISOTHERMAL AMPLIFICATION MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 28. GLOBAL POLYMERASE CHAIN REACTION MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 29. GLOBAL POLYMERASE CHAIN REACTION MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 30. GLOBAL POLYMERASE CHAIN REACTION MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 31. GLOBAL SEQUENCING MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 32. GLOBAL SEQUENCING MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 33. GLOBAL SEQUENCING MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 34. GLOBAL NEXT GENERATION SEQUENCING MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 35. GLOBAL NEXT GENERATION SEQUENCING MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 36. GLOBAL NEXT GENERATION SEQUENCING MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 37. GLOBAL SANGER SEQUENCING MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 38. GLOBAL SANGER SEQUENCING MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 39. GLOBAL SANGER SEQUENCING MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 40. GLOBAL RESPIRATORY INFECTION DIAGNOSTICS MARKET SIZE, BY SAMPLE TYPE, 2018-2032 (USD MILLION)
  • TABLE 41. GLOBAL BLOOD MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 42. GLOBAL BLOOD MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 43. GLOBAL BLOOD MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 44. GLOBAL NASAL SWAB MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 45. GLOBAL NASAL SWAB MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 46. GLOBAL NASAL SWAB MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 47. GLOBAL SALIVA MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 48. GLOBAL SALIVA MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 49. GLOBAL SALIVA MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 50. GLOBAL SPUTUM MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 51. GLOBAL SPUTUM MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 52. GLOBAL SPUTUM MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 53. GLOBAL THROAT SWAB MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 54. GLOBAL THROAT SWAB MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 55. GLOBAL THROAT SWAB MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 56. GLOBAL RESPIRATORY INFECTION DIAGNOSTICS MARKET SIZE, BY TEST MODE, 2018-2032 (USD MILLION)
  • TABLE 57. GLOBAL LABORATORY BASED MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 58. GLOBAL LABORATORY BASED MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 59. GLOBAL LABORATORY BASED MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 60. GLOBAL POINT OF CARE MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 61. GLOBAL POINT OF CARE MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 62. GLOBAL POINT OF CARE MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 63. GLOBAL RESPIRATORY INFECTION DIAGNOSTICS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 64. GLOBAL CLINICS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 65. GLOBAL CLINICS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 66. GLOBAL CLINICS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 67. GLOBAL HOME CARE SETTINGS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 68. GLOBAL HOME CARE SETTINGS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 69. GLOBAL HOME CARE SETTINGS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 70. GLOBAL HOSPITALS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 71. GLOBAL HOSPITALS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 72. GLOBAL HOSPITALS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 73. GLOBAL RESEARCH LABORATORIES MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 74. GLOBAL RESEARCH LABORATORIES MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 75. GLOBAL RESEARCH LABORATORIES MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 76. GLOBAL RESPIRATORY INFECTION DIAGNOSTICS MARKET SIZE, BY INFECTION TYPE, 2018-2032 (USD MILLION)
  • TABLE 77. GLOBAL INFLUENZA MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 78. GLOBAL INFLUENZA MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 79. GLOBAL INFLUENZA MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 80. GLOBAL RESPIRATORY SYNCYTIAL VIRUS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 81. GLOBAL RESPIRATORY SYNCYTIAL VIRUS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 82. GLOBAL RESPIRATORY SYNCYTIAL VIRUS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 83. GLOBAL RESPIRATORY INFECTION DIAGNOSTICS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 84. ASIA-PACIFIC RESPIRATORY INFECTION DIAGNOSTICS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 85. ASIA-PACIFIC RESPIRATORY INFECTION DIAGNOSTICS MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 86. ASIA-PACIFIC RESPIRATORY INFECTION DIAGNOSTICS MARKET SIZE, BY IMMUNOASSAY, 2018-2032 (USD MILLION)
  • TABLE 87. ASIA-PACIFIC RESPIRATORY INFECTION DIAGNOSTICS MARKET SIZE, BY MICROBIOLOGICAL CULTURE, 2018-2032 (USD MILLION)
  • TABLE 88. ASIA-PACIFIC RESPIRATORY INFECTION DIAGNOSTICS MARKET SIZE, BY MOLECULAR DIAGNOSTICS, 2018-2032 (USD MILLION)
  • TABLE 89. ASIA-PACIFIC RESPIRATORY INFECTION DIAGNOSTICS MARKET SIZE, BY SEQUENCING, 2018-2032 (USD MILLION)
  • TABLE 90. ASIA-PACIFIC RESPIRATORY INFECTION DIAGNOSTICS MARKET SIZE, BY SAMPLE TYPE, 2018-2032 (USD MILLION)
  • TABLE 91. ASIA-PACIFIC RESPIRATORY INFECTION DIAGNOSTICS MARKET SIZE, BY TEST MODE, 2018-2032 (USD MILLION)
  • TABLE 92. ASIA-PACIFIC RESPIRATORY INFECTION DIAGNOSTICS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 93. ASIA-PACIFIC RESPIRATORY INFECTION DIAGNOSTICS MARKET SIZE, BY INFECTION TYPE, 2018-2032 (USD MILLION)
  • TABLE 94. EUROPE RESPIRATORY INFECTION DIAGNOSTICS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 95. EUROPE RESPIRATORY INFECTION DIAGNOSTICS MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 96. EUROPE RESPIRATORY INFECTION DIAGNOSTICS MARKET SIZE, BY IMMUNOASSAY, 2018-2032 (USD MILLION)
  • TABLE 97. EUROPE RESPIRATORY INFECTION DIAGNOSTICS MARKET SIZE, BY MICROBIOLOGICAL CULTURE, 2018-2032 (USD MILLION)
  • TABLE 98. EUROPE RESPIRATORY INFECTION DIAGNOSTICS MARKET SIZE, BY MOLECULAR DIAGNOSTICS, 2018-2032 (USD MILLION)
  • TABLE 99. EUROPE RESPIRATORY INFECTION DIAGNOSTICS MARKET SIZE, BY SEQUENCING, 2018-2032 (USD MILLION)
  • TABLE 100. EUROPE RESPIRATORY INFECTION DIAGNOSTICS MARKET SIZE, BY SAMPLE TYPE, 2018-2032 (USD MILLION)
  • TABLE 101. EUROPE RESPIRATORY INFECTION DIAGNOSTICS MARKET SIZE, BY TEST MODE, 2018-2032 (USD MILLION)
  • TABLE 102. EUROPE RESPIRATORY INFECTION DIAGNOSTICS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 103. EUROPE RESPIRATORY INFECTION DIAGNOSTICS MARKET SIZE, BY INFECTION TYPE, 2018-2032 (USD MILLION)
  • TABLE 104. NORTH AMERICA RESPIRATORY INFECTION DIAGNOSTICS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 105. NORTH AMERICA RESPIRATORY INFECTION DIAGNOSTICS MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 106. NORTH AMERICA RESPIRATORY INFECTION DIAGNOSTICS MARKET SIZE, BY IMMUNOASSAY, 2018-2032 (USD MILLION)
  • TABLE 107. NORTH AMERICA RESPIRATORY INFECTION DIAGNOSTICS MARKET SIZE, BY MICROBIOLOGICAL CULTURE, 2018-2032 (USD MILLION)
  • TABLE 108. NORTH AMERICA RESPIRATORY INFECTION DIAGNOSTICS MARKET SIZE, BY MOLECULAR DIAGNOSTICS, 2018-2032 (USD MILLION)
  • TABLE 109. NORTH AMERICA RESPIRATORY INFECTION DIAGNOSTICS MARKET SIZE, BY SEQUENCING, 2018-2032 (USD MILLION)
  • TABLE 110. NORTH AMERICA RESPIRATORY INFECTION DIAGNOSTICS MARKET SIZE, BY SAMPLE TYPE, 2018-2032 (USD MILLION)
  • TABLE 111. NORTH AMERICA RESPIRATORY INFECTION DIAGNOSTICS MARKET SIZE, BY TEST MODE, 2018-2032 (USD MILLION)
  • TABLE 112. NORTH AMERICA RESPIRATORY INFECTION DIAGNOSTICS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 113. NORTH AMERICA RESPIRATORY INFECTION DIAGNOSTICS MARKET SIZE, BY INFECTION TYPE, 2018-2032 (USD MILLION)
  • TABLE 114. LATIN AMERICA RESPIRATORY INFECTION DIAGNOSTICS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 115. LATIN AMERICA RESPIRATORY INFECTION DIAGNOSTICS MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 116. LATIN AMERICA RESPIRATORY INFECTION DIAGNOSTICS MARKET SIZE, BY IMMUNOASSAY, 2018-2032 (USD MILLION)
  • TABLE 117. LATIN AMERICA RESPIRATORY INFECTION DIAGNOSTICS MARKET SIZE, BY MICROBIOLOGICAL CULTURE, 2018-2032 (USD MILLION)
  • TABLE 118. LATIN AMERICA RESPIRATORY INFECTION DIAGNOSTICS MARKET SIZE, BY MOLECULAR DIAGNOSTICS, 2018-2032 (USD MILLION)
  • TABLE 119. LATIN AMERICA RESPIRATORY INFECTION DIAGNOSTICS MARKET SIZE, BY SEQUENCING, 2018-2032 (USD MILLION)
  • TABLE 120. LATIN AMERICA RESPIRATORY INFECTION DIAGNOSTICS MARKET SIZE, BY SAMPLE TYPE, 2018-2032 (USD MILLION)
  • TABLE 121. LATIN AMERICA RESPIRATORY INFECTION DIAGNOSTICS MARKET SIZE, BY TEST MODE, 2018-2032 (USD MILLION)
  • TABLE 122. LATIN AMERICA RESPIRATORY INFECTION DIAGNOSTICS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 123. LATIN AMERICA RESPIRATORY INFECTION DIAGNOSTICS MARKET SIZE, BY INFECTION TYPE, 2018-2032 (USD MILLION)
  • TABLE 124. AFRICA RESPIRATORY INFECTION DIAGNOSTICS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 125. AFRICA RESPIRATORY INFECTION DIAGNOSTICS MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 126. AFRICA RESPIRATORY INFECTION DIAGNOSTICS MARKET SIZE, BY IMMUNOASSAY, 2018-2032 (USD MILLION)
  • TABLE 127. AFRICA RESPIRATORY INFECTION DIAGNOSTICS MARKET SIZE, BY MICROBIOLOGICAL CULTURE, 2018-2032 (USD MILLION)
  • TABLE 128. AFRICA RESPIRATORY INFECTION DIAGNOSTICS MARKET SIZE, BY MOLECULAR DIAGNOSTICS, 2018-2032 (USD MILLION)
  • TABLE 129. AFRICA RESPIRATORY INFECTION DIAGNOSTICS MARKET SIZE, BY SEQUENCING, 2018-2032 (USD MILLION)
  • TABLE 130. AFRICA RESPIRATORY INFECTION DIAGNOSTICS MARKET SIZE, BY SAMPLE TYPE, 2018-2032 (USD MILLION)
  • TABLE 131. AFRICA RESPIRATORY INFECTION DIAGNOSTICS MARKET SIZE, BY TEST MODE, 2018-2032 (USD MILLION)
  • TABLE 132. AFRICA RESPIRATORY INFECTION DIAGNOSTICS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 133. AFRICA RESPIRATORY INFECTION DIAGNOSTICS MARKET SIZE, BY INFECTION TYPE, 2018-2032 (USD MILLION)
  • TABLE 134. MIDDLE EAST RESPIRATORY INFECTION DIAGNOSTICS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 135. MIDDLE EAST RESPIRATORY INFECTION DIAGNOSTICS MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 136. MIDDLE EAST RESPIRATORY INFECTION DIAGNOSTICS MARKET SIZE, BY IMMUNOASSAY, 2018-2032 (USD MILLION)
  • TABLE 137. MIDDLE EAST RESPIRATORY INFECTION DIAGNOSTICS MARKET SIZE, BY MICROBIOLOGICAL CULTURE, 2018-2032 (USD MILLION)
  • TABLE 138. MIDDLE EAST RESPIRATORY INFECTION DIAGNOSTICS MARKET SIZE, BY MOLECULAR DIAGNOSTICS, 2018-2032 (USD MILLION)
  • TABLE 139. MIDDLE EAST RESPIRATORY INFECTION DIAGNOSTICS MARKET SIZE, BY SEQUENCING, 2018-2032 (USD MILLION)
  • TABLE 140. MIDDLE EAST RESPIRATORY INFECTION DIAGNOSTICS MARKET SIZE, BY SAMPLE TYPE, 2018-2032 (USD MILLION)
  • TABLE 141. MIDDLE EAST RESPIRATORY INFECTION DIAGNOSTICS MARKET SIZE, BY TEST MODE, 2018-2032 (USD MILLION)
  • TABLE 142. MIDDLE EAST RESPIRATORY INFECTION DIAGNOSTICS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 143. MIDDLE EAST RESPIRATORY INFECTION DIAGNOSTICS MARKET SIZE, BY INFECTION TYPE, 2018-2032 (USD MILLION)
  • TABLE 144. GLOBAL RESPIRATORY INFECTION DIAGNOSTICS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 145. NATO RESPIRATORY INFECTION DIAGNOSTICS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 146. NATO RESPIRATORY INFECTION DIAGNOSTICS MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 147. NATO RESPIRATORY INFECTION DIAGNOSTICS MARKET SIZE, BY IMMUNOASSAY, 2018-2032 (USD MILLION)
  • TABLE 148. NATO RESPIRATORY INFECTION DIAGNOSTICS MARKET SIZE, BY MICROBIOLOGICAL CULTURE, 2018-2032 (USD MILLION)
  • TABLE 149. NATO RESPIRATORY INFECTION DIAGNOSTICS MARKET SIZE, BY MOLECULAR DIAGNOSTICS, 2018-2032 (USD MILLION)
  • TABLE 150. NATO RESPIRATORY INFECTION DIAGNOSTICS MARKET SIZE, BY SEQUENCING, 2018-2032 (USD MILLION)
  • TABLE 151. NATO RESPIRATORY INFECTION DIAGNOSTICS MARKET SIZE, BY SAMPLE TYPE, 2018-2032 (USD MILLION)
  • TABLE 152. NATO RESPIRATORY INFECTION DIAGNOSTICS MARKET SIZE, BY TEST MODE, 2018-2032 (USD MILLION)
  • TABLE 153. NATO RESPIRATORY INFECTION DIAGNOSTICS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 154. NATO RESPIRATORY INFECTION DIAGNOSTICS MARKET SIZE, BY INFECTION TYPE, 2018-2032 (USD MILLION)
  • TABLE 155. G7 RESPIRATORY INFECTION DIAGNOSTICS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 156. G7 RESPIRATORY INFECTION DIAGNOSTICS MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 157. G7 RESPIRATORY INFECTION DIAGNOSTICS MARKET SIZE, BY IMMUNOASSAY, 2018-2032 (USD MILLION)
  • TABLE 158. G7 RESPIRATORY INFECTION DIAGNOSTICS MARKET SIZE, BY MICROBIOLOGICAL CULTURE, 2018-2032 (USD MILLION)
  • TABLE 159. G7 RESPIRATORY INFECTION DIAGNOSTICS MARKET SIZE, BY MOLECULAR DIAGNOSTICS, 2018-2032 (USD MILLION)
  • TABLE 160. G7 RESPIRATORY INFECTION DIAGNOSTICS MARKET SIZE, BY SEQUENCING, 2018-2032 (USD MILLION)
  • TABLE 161. G7 RESPIRATORY INFECTION DIAGNOSTICS MARKET SIZE, BY SAMPLE TYPE, 2018-2032 (USD MILLION)
  • TABLE 162. G7 RESPIRATORY INFECTION DIAGNOSTICS MARKET SIZE, BY TEST MODE, 2018-2032 (USD MILLION)
  • TABLE 163. G7 RESPIRATORY INFECTION DIAGNOSTICS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 164. G7 RESPIRATORY INFECTION DIAGNOSTICS MARKET SIZE, BY INFECTION TYPE, 2018-2032 (USD MILLION)
  • TABLE 165. BRICS RESPIRATORY INFECTION DIAGNOSTICS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 166. BRICS RESPIRATORY INFECTION DIAGNOSTICS MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 167. BRICS RESPIRATORY INFECTION DIAGNOSTICS MARKET SIZE, BY IMMUNOASSAY, 2018-2032 (USD MILLION)
  • TABLE 168. BRICS RESPIRATORY INFECTION DIAGNOSTICS MARKET SIZE, BY MICROBIOLOGICAL CULTURE, 2018-2032 (USD MILLION)
  • TABLE 169. BRICS RESPIRATORY INFECTION DIAGNOSTICS MARKET SIZE, BY MOLECULAR DIAGNOSTICS, 2018-2032 (USD MILLION)
  • TABLE 170. BRICS RESPIRATORY INFECTION DIAGNOSTICS MARKET SIZE, BY SEQUENCING, 2018-2032 (USD MILLION)
  • TABLE 171. BRICS RESPIRATORY INFECTION DIAGNOSTICS MARKET SIZE, BY SAMPLE TYPE, 2018-2032 (USD MILLION)
  • TABLE 172. BRICS RESPIRATORY INFECTION DIAGNOSTICS MARKET SIZE, BY TEST MODE, 2018-2032 (USD MILLION)
  • TABLE 173. BRICS RESPIRATORY INFECTION DIAGNOSTICS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 174. BRICS RESPIRATORY INFECTION DIAGNOSTICS MARKET SIZE, BY INFECTION TYPE, 2018-2032 (USD MILLION)
  • TABLE 175. EUROPEAN UNION RESPIRATORY INFECTION DIAGNOSTICS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 176. EUROPEAN UNION RESPIRATORY INFECTION DIAGNOSTICS MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 177. EUROPEAN UNION RESPIRATORY INFECTION DIAGNOSTICS MARKET SIZE, BY IMMUNOASSAY, 2018-2032 (USD MILLION)
  • TABLE 178. EUROPEAN UNION RESPIRATORY INFECTION DIAGNOSTICS MARKET SIZE, BY MICROBIOLOGICAL CULTURE, 2018-2032 (USD MILLION)
  • TABLE 179. EUROPEAN UNION RESPIRATORY INFECTION DIAGNOSTICS MARKET SIZE, BY MOLECULAR DIAGNOSTICS, 2018-2032 (USD MILLION)
  • TABLE 180. EUROPEAN UNION RESPIRATORY INFECTION DIAGNOSTICS MARKET SIZE, BY SEQUENCING, 2018-2032 (USD MILLION)
  • TABLE 181. EUROPEAN UNION RESPIRATORY INFECTION DIAGNOSTICS MARKET SIZE, BY SAMPLE TYPE, 2018-2032 (USD MILLION)
  • TABLE 182. EUROPEAN UNION RESPIRATORY INFECTION DIAGNOSTICS MARKET SIZE, BY TEST MODE, 2018-2032 (USD MILLION)
  • TABLE 183. EUROPEAN UNION RESPIRATORY INFECTION DIAGNOSTICS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 184. EUROPEAN UNION RESPIRATORY INFECTION DIAGNOSTICS MARKET SIZE, BY INFECTION TYPE, 2018-2032 (USD MILLION)
  • TABLE 185. ASEAN RESPIRATORY INFECTION DIAGNOSTICS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 186. ASEAN RESPIRATORY INFECTION DIAGNOSTICS MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 187. ASEAN RESPIRATORY INFECTION DIAGNOSTICS MARKET SIZE, BY IMMUNOASSAY, 2018-2032 (USD MILLION)
  • TABLE 188. ASEAN RESPIRATORY INFECTION DIAGNOSTICS MARKET SIZE, BY MICROBIOLOGICAL CULTURE, 2018-2032 (USD MILLION)
  • TABLE 189. ASEAN RESPIRATORY INFECTION DIAGNOSTICS MARKET SIZE, BY MOLECULAR DIAGNOSTICS, 2018-2032 (USD MILLION)
  • TABLE 190. ASEAN RESPIRATORY INFECTION DIAGNOSTICS MARKET SIZE, BY SEQUENCING, 2018-2032 (USD MILLION)
  • TABLE 191. ASEAN RESPIRATORY INFECTION DIAGNOSTICS MARKET SIZE, BY SAMPLE TYPE, 2018-2032 (USD MILLION)
  • TABLE 192. ASEAN RESPIRATORY INFECTION DIAGNOSTICS MARKET SIZE, BY TEST MODE, 2018-2032 (USD MILLION)
  • TABLE 193. ASEAN RESPIRATORY INFECTION DIAGNOSTICS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 194. ASEAN RESPIRATORY INFECTION DIAGNOSTICS MARKET SIZE, BY INFECTION TYPE, 2018-2032 (USD MILLION)
  • TABLE 195. GCC RESPIRATORY INFECTION DIAGNOSTICS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 196. GCC RESPIRATORY INFECTION DIAGNOSTICS MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 197. GCC RESPIRATORY INFECTION DIAGNOSTICS MARKET SIZE, BY IMMUNOASSAY, 2018-2032 (USD MILLION)
  • TABLE 198. GCC RESPIRATORY INFECTION DIAGNOSTICS MARKET SIZE, BY MICROBIOLOGICAL CULTURE, 2018-2032 (USD MILLION)
  • TABLE 199. GCC RESPIRATORY INFECTION DIAGNOSTICS MARKET SIZE, BY MOLECULAR DIAGNOSTICS, 2018-2032 (USD MILLION)
  • TABLE 200. GCC RESPIRATORY INFECTION DIAGNOSTICS MARKET SIZE, BY SEQUENCING, 2018-2032 (USD MILLION)
  • TABLE 201. GCC RESPIRATORY INFECTION DIAGNOSTICS MARKET SIZE, BY SAMPLE TYPE, 2018-2032 (USD MILLION)
  • TABLE 202. GCC RESPIRATORY INFECTION DIAGNOSTICS MARKET SIZE, BY TEST MODE, 2018-2032 (USD MILLION)
  • TABLE 203. GCC RESPIRATORY INFECTION DIAGNOSTICS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 204. GCC RESPIRATORY INFECTION DIAGNOSTICS MARKET SIZE, BY INFECTION TYPE, 2018-2032 (USD MILLION)
  • TABLE 205. GLOBAL RESPIRATORY INFECTION DIAGNOSTICS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 206. CHINA RESPIRATORY INFECTION DIAGNOSTICS MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 207. CHINA RESPIRATORY INFECTION DIAGNOSTICS MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 208. CHINA RESPIRATORY INFECTION DIAGNOSTICS MARKET SIZE, BY IMMUNOASSAY, 2018-2032 (USD MILLION)
  • TABLE 209. CHINA RESPIRATORY INFECTION DIAGNOSTICS MARKET SIZE, BY MICROBIOLOGICAL CULTURE, 2018-2032 (USD MILLION)
  • TABLE 210. CHINA RESPIRATORY INFECTION DIAGNOSTICS MARKET SIZE, BY MOLECULAR DIAGNOSTICS, 2018-2032 (USD MILLION)
  • TABLE 211. CHINA RESPIRATORY INFECTION DIAGNOSTICS MARKET SIZE, BY SEQUENCING, 2018-2032 (USD MILLION)
  • TABLE 212. CHINA RESPIRATORY INFECTION DIAGNOSTICS MARKET SIZE, BY SAMPLE TYPE, 2018-2032 (USD MILLION)
  • TABLE 213. CHINA RESPIRATORY INFECTION DIAGNOSTICS MARKET SIZE, BY TEST MODE, 2018-2032 (USD MILLION)
  • TABLE 214. CHINA RESPIRATORY INFECTION DIAGNOSTICS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 215. CHINA RESPIRATORY INFECTION DIAGNOSTICS MARKET SIZE, BY INFECTION TYPE, 2018-2032 (USD MILLION)
  • TABLE 216. UNITED STATES RESPIRATORY INFECTION DIAGNOSTICS MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 217. UNITED STATES RESPIRATORY INFECTION DIAGNOSTICS MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 218. UNITED STATES RESPIRATORY INFECTION DIAGNOSTICS MARKET SIZE, BY IMMUNOASSAY, 2018-2032 (USD MILLION)
  • TABLE 219. UNITED STATES RESPIRATORY INFECTION DIAGNOSTICS MARKET SIZE, BY MICROBIOLOGICAL CULTURE, 2018-2032 (USD MILLION)
  • TABLE 220. UNITED STATES RESPIRATORY INFECTION DIAGNOSTICS MARKET SIZE, BY MOLECULAR DIAGNOSTICS, 2018-2032 (USD MILLION)
  • TABLE 221. UNITED STATES RESPIRATORY INFECTION DIAGNOSTICS MARKET SIZE, BY SEQUENCING, 2018-2032 (USD MILLION)
  • TABLE 222. UNITED STATES RESPIRATORY INFECTION DIAGNOSTICS MARKET SIZE, BY SAMPLE TYPE, 2018-2032 (USD MILLION)
  • TABLE 223. UNITED STATES RESPIRATORY INFECTION DIAGNOSTICS MARKET SIZE, BY TEST MODE, 2018-2032 (USD MILLION)
  • TABLE 224. UNITED STATES RESPIRATORY INFECTION DIAGNOSTICS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 225. UNITED STATES RESPIRATORY INFECTION DIAGNOSTICS MARKET SIZE, BY INFECTION TYPE, 2018-2032 (USD MILLION)
  • TABLE 226. JAPAN RESPIRATORY INFECTION DIAGNOSTICS MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 227. JAPAN RESPIRATORY INFECTION DIAGNOSTICS MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 228. JAPAN RESPIRATORY INFECTION DIAGNOSTICS MARKET SIZE, BY IMMUNOASSAY, 2018-2032 (USD MILLION)
  • TABLE 229. JAPAN RESPIRATORY INFECTION DIAGNOSTICS MARKET SIZE, BY MICROBIOLOGICAL CULTURE, 2018-2032 (USD MILLION)
  • TABLE 230. JAPAN RESPIRATORY INFECTION DIAGNOSTICS MARKET SIZE, BY MOLECULAR DIAGNOSTICS, 2018-2032 (USD MILLION)
  • TABLE 231. JAPAN RESPIRATORY INFECTION DIAGNOSTICS MARKET SIZE, BY SEQUENCING, 2018-2032 (USD MILLION)
  • TABLE 232. JAPAN RESPIRATORY INFECTION DIAGNOSTICS MARKET SIZE, BY SAMPLE TYPE, 2018-2032 (USD MILLION)
  • TABLE 233. JAPAN RESPIRATORY INFECTION DIAGNOSTICS MARKET SIZE, BY TEST MODE, 2018-2032 (USD MILLION)
  • TABLE 234. JAPAN RESPIRATORY INFECTION DIAGNOSTICS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 235. JAPAN RESPIRATORY INFECTION DIAGNOSTICS MARKET SIZE, BY INFECTION TYPE, 2018-2032 (USD MILLION)
  • TABLE 236. INDIA RESPIRATORY INFECTION DIAGNOSTICS MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 237. INDIA RESPIRATORY INFECTION DIAGNOSTICS MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 238. INDIA RESPIRATORY INFECTION DIAGNOSTICS MARKET SIZE, BY IMMUNOASSAY, 2018-2032 (USD MILLION)
  • TABLE 239. INDIA RESPIRATORY INFECTION DIAGNOSTICS MARKET SIZE, BY MICROBIOLOGICAL CULTURE, 2018-2032 (USD MILLION)
  • TABLE 240. INDIA RESPIRATORY INFECTION DIAGNOSTICS MARKET SIZE, BY MOLECULAR DIAGNOSTICS, 2018-2032 (USD MILLION)
  • TABLE 241. INDIA RESPIRATORY INFECTION DIAGNOSTICS MARKET SIZE, BY SEQUENCING, 2018-2032 (USD MILLION)
  • TABLE 242. INDIA RESPIRATORY INFECTION DIAGNOSTICS MARKET SIZE, BY SAMPLE TYPE, 2018-2032 (USD MILLION)
  • TABLE 243. INDIA RESPIRATORY INFECTION DIAGNOSTICS MARKET SIZE, BY TEST MODE, 2018-2032 (USD MILLION)
  • TABLE 244. INDIA RESPIRATORY INFECTION DIAGNOSTICS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 245. INDIA RESPIRATORY INFECTION DIAGNOSTICS MARKET SIZE, BY INFECTION TYPE, 2018-2032 (USD MILLION)
  • TABLE 246. GERMANY RESPIRATORY INFECTION DIAGNOSTICS MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 247. GERMANY RESPIRATORY INFECTION DIAGNOSTICS MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 248. GERMANY RESPIRATORY INFECTION DIAGNOSTICS MARKET SIZE, BY IMMUNOASSAY, 2018-2032 (USD MILLION)
  • TABLE 249. GERMANY RESPIRATORY INFECTION DIAGNOSTICS MARKET SIZE, BY MICROBIOLOGICAL CULTURE, 2018-2032 (USD MILLION)
  • TABLE 250. GERMANY RESPIRATORY INFECTION DIAGNOSTICS MARKET SIZE, BY MOLECULAR DIAGNOSTICS, 2018-2032 (USD MILLION)
  • TABLE 251. GERMANY RESPIRATORY INFECTION DIAGNOSTICS MARKET SIZE, BY SEQUENCING, 2018-2032 (USD MILLION)
  • TABLE 252. GERMANY RESPIRATORY INFECTION DIAGNOSTICS MARKET SIZE, BY SAMPLE TYPE, 2018-2032 (USD MILLION)
  • TABLE 253. GERMANY RESPIRATORY INFECTION DIAGNOSTICS MARKET SIZE, BY TEST MODE, 2018-2032 (USD MILLION)
  • TABLE 254. GERMANY RESPIRATORY INFECTION DIAGNOSTICS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 255. GERMANY RESPIRATORY INFECTION DIAGNOSTICS MARKET SIZE, BY INFECTION TYPE, 2018-2032 (USD MILLION)
  • TABLE 256. UNITED KINGDOM RESPIRATORY INFECTION DIAGNOSTICS MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 257. UNITED KINGDOM RESPIRATORY INFECTION DIAGNOSTICS MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 258. UNITED KINGDOM RESPIRATORY INFECTION DIAGNOSTICS MARKET SIZE, BY IMMUNOASSAY, 2018-2032 (USD MILLION)
  • TABLE 259. UNITED KINGDOM RESPIRATORY INFECTION DIAGNOSTICS MARKET SIZE, BY MICROBIOLOGICAL CULTURE, 2018-2032 (USD MILLION)
  • TABLE 260. UNITED KINGDOM RESPIRATORY INFECTION DIAGNOSTICS MARKET SIZE, BY MOLECULAR DIAGNOSTICS, 2018-2032 (USD MILLION)
  • TABLE 261. UNITED KINGDOM RESPIRATORY INFECTION DIAGNOSTICS MARKET SIZE, BY SEQUENCING, 2018-2032 (USD MILLION)
  • TABLE 262. UNITED KINGDOM RESPIRATORY INFECTION DIAGNOSTICS MARKET SIZE, BY SAMPLE TYPE, 2018-2032 (USD MILLION)
  • TABLE 263. UNITED KINGDOM RESPIRATORY INFECTION DIAGNOSTICS MARKET SIZE, BY TEST MODE, 2018-2032 (USD MILLION)
  • TABLE 264. UNITED KINGDOM RESPIRATORY INFECTION DIAGNOSTICS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 265. UNITED KINGDOM RESPIRATORY INFECTION DIAGNOSTICS MARKET SIZE, BY INFECTION TYPE, 2018-2032 (USD MILLION)
  • TABLE 266. AUSTRALIA RESPIRATORY INFECTION DIAGNOSTICS MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 267. AUSTRALIA RESPIRATORY INFECTION DIAGNOSTICS MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 268. AUSTRALIA RESPIRATORY INFECTION DIAGNOSTICS MARKET SIZE, BY IMMUNOASSAY, 2018-2032 (USD MILLION)
  • TABLE 269. AUSTRALIA RESPIRATORY INFECTION DIAGNOSTICS MARKET SIZE, BY MICROBIOLOGICAL CULTURE, 2018-2032 (USD MILLION)
  • TABLE 270. AUSTRALIA RESPIRATORY INFECTION DIAGNOSTICS MARKET SIZE, BY MOLECULAR DIAGNOSTICS, 2018-2032 (USD MILLION)
  • TABLE 271. AUSTRALIA RESPIRATORY INFECTION DIAGNOSTICS MARKET SIZE, BY SEQUENCING, 2018-2032 (USD MILLION)
  • TABLE 272. AUSTRALIA RESPIRATORY INFECTION DIAGNOSTICS MARKET SIZE, BY SAMPLE TYPE, 2018-2032 (USD MILLION)
  • TABLE 273. AUSTRALIA RESPIRATORY INFECTION DIAGNOSTICS MARKET SIZE, BY TEST MODE, 2018-2032 (USD MILLION)
  • TABLE 274. AUSTRALIA RESPIRATORY INFECTION DIAGNOSTICS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 275. AUSTRALIA RESPIRATORY INFECTION DIAGNOSTICS MARKET SIZE, BY INFECTION TYPE, 2018-2032 (USD MILLION)
  • TABLE 276. FRANCE RESPIRATORY INFECTION DIAGNOSTICS MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 277. FRANCE RESPIRATORY INFECTION DIAGNOSTICS MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 278. FRANCE RESPIRATORY INFECTION DIAGNOSTICS MARKET SIZE, BY IMMUNOASSAY, 2018-2032 (USD MILLION)
  • TABLE 279. FRANCE RESPIRATORY INFECTION DIAGNOSTICS MARKET SIZE, BY MICROBIOLOGICAL CULTURE, 2018-2032 (USD MILLION)
  • TABLE 280. FRANCE RESPIRATORY INFECTION DIAGNOSTICS MARKET SIZE, BY MOLECULAR DIAGNOSTICS, 2018-2032 (USD MILLION)
  • TABLE 281. FRANCE RESPIRATORY INFECTION DIAGNOSTICS MARKET SIZE, BY SEQUENCING, 2018-2032 (USD MILLION)
  • TABLE 282. FRANCE RESPIRATORY INFECTION DIAGNOSTICS MARKET SIZE, BY SAMPLE TYPE, 2018-2032 (USD MILLION)
  • TABLE 283. FRANCE RESPIRATORY INFECTION DIAGNOSTICS MARKET SIZE, BY TEST MODE, 2018-2032 (USD MILLION)
  • TABLE 284. FRANCE RESPIRATORY INFECTION DIAGNOSTICS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 285. FRANCE RESPIRATORY INFECTION DIAGNOSTICS MARKET SIZE, BY INFECTION TYPE, 2018-2032 (USD MILLION)
  • TABLE 286. SOUTH KOREA RESPIRATORY INFECTION DIAGNOSTICS MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 287. SOUTH KOREA RESPIRATORY INFECTION DIAGNOSTICS MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 288. SOUTH KOREA RESPIRATORY INFECTION DIAGNOSTICS MARKET SIZE, BY IMMUNOASSAY, 2018-2032 (USD MILLION)
  • TABLE 289. SOUTH KOREA RESPIRATORY INFECTION DIAGNOSTICS MARKET SIZE, BY MICROBIOLOGICAL CULTURE, 2018-2032 (USD MILLION)
  • TABLE 290. SOUTH KOREA RESPIRATORY INFECTION DIAGNOSTICS MARKET SIZE, BY MOLECULAR DIAGNOSTICS, 2018-2032 (USD MILLION)
  • TABLE 291. SOUTH KOREA RESPIRATORY INFECTION DIAGNOSTICS MARKET SIZE, BY SEQUENCING, 2018-2032 (USD MILLION)
  • TABLE 292. SOUTH KOREA RESPIRATORY INFECTION DIAGNOSTICS MARKET SIZE, BY SAMPLE TYPE, 2018-2032 (USD MILLION)
  • TABLE 293. SOUTH KOREA RESPIRATORY INFECTION DIAGNOSTICS MARKET SIZE, BY TEST MODE, 2018-2032 (USD MILLION)
  • TABLE 294. SOUTH KOREA RESPIRATORY INFECTION DIAGNOSTICS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 295. SOUTH KOREA RESPIRATORY INFECTION DIAGNOSTICS MARKET SIZE, BY INFECTION TYPE, 2018-2032 (USD MILLION)
  • TABLE 296. ITALY RESPIRATORY INFECTION DIAGNOSTICS MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 297. ITALY RESPIRATORY INFECTION DIAGNOSTICS MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 298. ITALY RESPIRATORY INFECTION DIAGNOSTICS MARKET SIZE, BY IMMUNOASSAY, 2018-2032 (USD MILLION)
  • TABLE 299. ITALY RESPIRATORY INFECTION DIAGNOSTICS MARKET SIZE, BY MICROBIOLOGICAL CULTURE, 2018-2032 (USD MILLION)
  • TABLE 300. ITALY RESPIRATORY INFECTION DIAGNOSTICS MARKET SIZE, BY MOLECULAR DIAGNOSTICS, 2018-2032 (USD MILLION)
  • TABLE 301. ITALY RESPIRATORY INFECTION DIAGNOSTICS MARKET SIZE, BY SEQUENCING, 2018-2032 (USD MILLION)
  • TABLE 302. ITALY RESPIRATORY INFECTION DIAGNOSTICS MARKET SIZE, BY SAMPLE TYPE, 2018-2032 (USD MILLION)
  • TABLE 303. ITALY RESPIRATORY INFECTION DIAGNOSTICS MARKET SIZE, BY TEST MODE, 2018-2032 (USD MILLION)
  • TABLE 304. ITALY RESPIRATORY INFECTION DIAGNOSTICS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 305. ITALY RESPIRATORY INFECTION DIAGNOSTICS MARKET SIZE, BY INFECTION TYPE, 2018-2032 (USD MILLION)
  • TABLE 306. CANADA RESPIRATORY INFECTION DIAGNOSTICS MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 307. CANADA RESPIRATORY INFECTION DIAGNOSTICS MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 308. CANADA RESPIRATORY INFECTION DIAGNOSTICS MARKET SIZE, BY IMMUNOASSAY, 2018-2032 (USD MILLION)
  • TABLE 309. CANADA RESPIRATORY INFECTION DIAGNOSTICS MARKET SIZE, BY MICROBIOLOGICAL CULTURE, 2018-2032 (USD MILLION)
  • TABLE 310. CANADA RESPIRATORY INFECTION DIAGNOSTICS MARKET SIZE, BY MOLECULAR DIAGNOSTICS, 2018-2032 (USD MILLION)
  • TABLE 311. CANADA RESPIRATORY INFECTION DIAGNOSTICS MARKET SIZE, BY SEQUENCING, 2018-2032 (USD MILLION)
  • TABLE 312. CANADA RESPIRATORY INFECTION DIAGNOSTICS MARKET SIZE, BY SAMPLE TYPE, 2018-2032 (USD MILLION)
  • TABLE 313. CANADA RESPIRATORY INFECTION DIAGNOSTICS MARKET SIZE, BY TEST MODE, 2018-2032 (USD MILLION)
  • TABLE 314. CANADA RESPIRATORY INFECTION DIAGNOSTICS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 315. CANADA RESPIRATORY INFECTION DIAGNOSTICS MARKET SIZE, BY INFECTION TYPE, 2018-2032 (USD MILLION)
  • TABLE 316. RUSSIA RESPIRATORY INFECTION DIAGNOSTICS MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 317. RUSSIA RESPIRATORY INFECTION DIAGNOSTICS MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 318. RUSSIA RESPIRATORY INFECTION DIAGNOSTICS MARKET SIZE, BY IMMUNOASSAY, 2018-2032 (USD MILLION)
  • TABLE 319. RUSSIA RESPIRATORY INFECTION DIAGNOSTICS MARKET SIZE, BY MICROBIOLOGICAL CULTURE, 2018-2032 (USD MILLION)
  • TABLE 320. RUSSIA RESPIRATORY INFECTION DIAGNOSTICS MARKET SIZE, BY MOLECULAR DIAGNOSTICS, 2018-2032 (USD MILLION)
  • TABLE 321. RUSSIA RESPIRATORY INFECTION DIAGNOSTICS MARKET SIZE, BY SEQUENCING, 2018-2032 (USD MILLION)
  • TABLE 322. RUSSIA RESPIRATORY INFECTION DIAGNOSTICS MARKET SIZE, BY SAMPLE TYPE, 2018-2032 (USD MILLION)
  • TABLE 323. RUSSIA RESPIRATORY INFECTION DIAGNOSTICS MARKET SIZE, BY TEST MODE, 2